Edition:
India

VBI Vaccines Inc (VBIV.OQ)

VBIV.OQ on NASDAQ Stock Exchange Capital Market

3.03USD
1:30am IST
Change (% chg)

$-0.16 (-5.02%)
Prev Close
$3.19
Open
$3.19
Day's High
$3.19
Day's Low
$3.02
Volume
75,985
Avg. Vol
53,860
52-wk High
$5.10
52-wk Low
$2.82

Latest Key Developments (Source: Significant Developments)

VBI Vaccines Announces Completion Of Enrollment In Protect Phase 3 Clinical Study For Sci-B-Vac Hepatitis B Vaccine
Thursday, 19 Apr 2018 

April 19 (Reuters) - VBI Vaccines Inc ::VBI VACCINES ANNOUNCES COMPLETION OF ENROLLMENT IN PROTECT PHASE 3 CLINICAL STUDY FOR SCI-B-VAC® HEPATITIS B VACCINE.VBI VACCINES INC - TOPLINE DATA FROM PROTECT STUDY ARE EXPECTED MID-YEAR 2019.  Full Article

Vbi Vaccines Announces Voluntary Delisting From The Toronto Stock Exchange
Tuesday, 13 Mar 2018 

March 12 (Reuters) - Vbi Vaccines Inc ::VBI VACCINES ANNOUNCES VOLUNTARY DELISTING FROM THE TORONTO STOCK EXCHANGE.VBI VACCINES - BOARD DECIDED TO VOLUNTARILY DELIST FROM TSX DUE TO VERY LIMITED TRADING ACTIVITY OF CO'S SHARES ON TSX.VBI VACCINES - LIMITED TRADING ACTIVITY OF CO'S SHARES ON TSX NO LONGER JUSTIFIES COSTS REQUIRED TO MAINTAIN DUAL-LISTING.VBI VACCINES - CO WILL CONTINUE TO HAVE "SIGNIFICANT" OPERATIONAL PRESENCE IN OTTAWA, CANADA.VBI VACCINES INC - SHARES WILL BE DELISTED FROM TSX, EFFECTIVE AT CLOSE OF TRADING ON MARCH 23.  Full Article

VBI Vaccines Announces First Patient Dosing In Phase 3 Clinical Program For Sci-B-Vac Hepatitis B Vaccine
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Vbi Vaccines Inc ::VBI VACCINES ANNOUNCES FIRST PATIENT DOSING IN PHASE 3 CLINICAL PROGRAM FOR SCI-B-VAC HEPATITIS B VACCINE.VBI VACCINES SAYS HEADLINE DATA FROM THE 15-MONTH PHASE 3 PROGRAM EXPECTED IN Q2 2019.VBI VACCINES SAYS 4,800 SUBJECTS EXPECTED TO ENROLL IN TRIAL ACROSS TWO PHASE 3 STUDIES, PROTECT AND CONSTANT.VBI VACCINES SAYS EXPECT TO SUBMIT MARKETING AUTHORIZATION APPLICATIONS FOR SCI-B-VAC TO U.S., EUROPEAN, CANADIAN AUTHORITIES IN 2019.  Full Article

VBI Vaccines announces full exercise of option to purchase additional shares, upsized registered direct offering for proceeds of $71.9 mln
Monday, 30 Oct 2017 

Oct 30 (Reuters) - VBI Vaccines Inc -:VBI Vaccines announces full exercise of underwriters’ option to purchase additional shares and upsized registered direct offering for aggregate proceeds of $71.9 million.VBI Vaccines Inc - ‍in addition, VBI's previously announced concurrent registered direct offering was upsized from US$20.8 million to US$22.8 million​.  Full Article

VBI vaccines prices concurrent public offering and registered direct offering
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - VBI Vaccines Inc :VBI Vaccines prices concurrent public offering and registered direct offering for aggregate proceeds of $63.5 million.Vbi Vaccines Inc - ‍pricing of offering at a price to public of US$3.05 per share​.  Full Article

VBI Vaccines announces proposed concurrent public offering
Thursday, 26 Oct 2017 

Oct 25 (Reuters) - VBI Vaccines Inc ::VBI Vaccines announces proposed concurrent public offering and registered direct offering of common shares.VBI Vaccines- to use proceeds from offerings to fund pivotal phase III clinical program for SCI-B-VAC in U.S., Europe, Canada​.VBI Vaccines Inc - ‍ to also use proceeds from offerings for funding phase I/IIA clinical study of VBI-1901 for glioblastoma multiforme, among others.  Full Article

VBI vaccines says Egidio Nascimento, has been named chief financial officer of company
Tuesday, 27 Sep 2016 

VBI Vaccines Inc :Says Egidio Nascimento, has been named chief financial officer of company.  Full Article

VBI Vaccines to continue Phase I Trial of its CMV Vaccine Candidate
Monday, 22 Aug 2016 

Vbi Vaccines Inc : Data safety monitoring board has no objection to co continuing enrollment in phase i clinical study to evaluate preventative cytomegalovirus vaccine candidate .Says will continue to share clinical trial safety data with Health Canada periodically throughout study.  Full Article

VBI Vaccines files for mixed shelf of upto $150 mln
Saturday, 23 Jul 2016 

Vbi Vaccines Inc :VBI Vaccines Inc files for mixed shelf of upto $150 million - SEC filing.  Full Article

VBI Vaccines applies eVLP platform in development of vaccine candidate to prevent zika virus
Tuesday, 19 Jul 2016 

VBI Vaccines Inc : VBI Vaccines applies its EVLP platform in development of a novel vaccine candidate to prevent Zika virus .VBI is developing a bivalent Zika vaccine candidate consisting of e glycoprotein and ns1 glycoprotein.  Full Article

BRIEF-VBI Vaccines Announces Positive Final Phase 1 Study Results Of Preventative CMV Vaccine

* VBI VACCINES ANNOUNCES POSITIVE FINAL PHASE 1 STUDY RESULTS OF PREVENTATIVE CMV VACCINE